|
|
Volumn 13, Issue 4, 2009, Pages 365-366
|
|
What we have learned from the xaliproden Sanofi-aventis trials
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CHOLINESTERASE INHIBITOR;
MEMANTINE;
PLACEBO;
XALIPRODEN;
ALZHEIMER DISEASE;
ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE;
ARTICLE;
BRAIN ATROPHY;
BRAIN SIZE;
BRAIN VENTRICLE DILATATION;
CLINICAL ASSESSMENT TOOL;
CLINICAL DEMENTIA RATING SCALE;
CLINICAL TRIAL;
DISEASE COURSE;
DRUG EFFICACY;
FOLLOW UP;
HUMAN;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PRIORITY JOURNAL;
RISK BENEFIT ANALYSIS;
TREATMENT DURATION;
ALZHEIMER DISEASE;
BIOLOGICAL MARKERS;
HUMANS;
MAGNETIC RESONANCE IMAGING;
NAPHTHALENES;
PYRIDINES;
RANDOMIZED CONTROLLED TRIALS AS TOPIC;
RESEARCH DESIGN;
|
|
EID: 65249118188
PISSN: 12797707
EISSN: None
Source Type: Journal
DOI: 10.1007/s12603-009-0045-6 Document Type: Article |
|
Times cited : (16)
|
|
References (0)
|
